Our combined preclinical and clinical results provide robust characterizations of EGFR-D770>GY and other EGFR exon 20 insertion mutants with a resulting G770 equivalent change, which comprise approximately 4% of all EGFR exon 20 mutations in lung cancer. This evidence concerns the gene EGFR and lung carcinoma.